Clinical Trial Update: Low-Dose Apixaban Added to Standard Heparin Lock Versus Heparin Lock Alone to Prevent Tunneled Hemodialysis Catheters Dysfunction (APICATH-HD) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating adding low-dose apixaban to standard heparin lock to prevent tunneled hemodialysis catheter dysfunction; recruitment no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease

Drugs mentioned

• Eliquis (apixaban)
• Heparin (unfractionated heparin)

Snippet

Sponsor: Hospital Civil de Guadalajara | Conditions: Hemodialysis Access Failure, Kidney Disease, End-Stage | Phase 4 | Status: NOT_YET_RECRUITING